Perindopril

Regulated restrictive practice · chemical restraint reference

If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.

Perindopril · RP Check

§01

↗TGA PIT1✓

TGA-approved indications

the treatment of hypertension
the treatment of heart failure
patients with established coronary artery disease ( see section 5.1 - Pharmacodynamic properties ) who are stable on concomitant therapy and have no heart failure to reduce the risk of non-fatal myocardial infarction or cardiac arrest

§02

↗PBST2✓

PBS-subsidised indications

The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient.

§03

Adverse effects

Common (top 5)

↗TGA PIT1✓

dizziness
headache
paraesthesia
vertigo
visual disturbances

Serious

§04

↗TGA PIT1✓

Contraindications

in patients with a history of previous hypersensitivity to the active ingredient perindopril, ACE- inhibitors or any of the excipient ingredients present in Perindopril
during pregnancy and for lactating women
in patients with bilateral or unilateral renal artery stenosis ( see section 4.4 - Special warnings and precautions for use )
in patients with a history of hereditary and/or idiopathic angioedema or angioedema associated with previous ACE-inhibitor treatment ( see section 4.4 - Special warnings and precautions for use)
in patients receiving extracorporeal treatments leading to contact of blood with negatively charged surfaces such as dialysis or haemofiltration with certain high-flux membranes (e.g. polyacrylonitrile membranes such as “AN69”) and low density lipoprotein apheresis with dextran sulfate due to increased risk of severe anaphylactoid reactions following treatment with ACE inhibitors. This combination should therefore be avoided, either by use of alternative antihypertensive medicines or alternative membranes (e.g. cuprophane or polysulfone (PSF)) ( see section 4.4 - Special warnings and precautions for use and section 4.5 - Interactions with other medicines and other forms of interactions )

§05

Mechanism & pharmacology

“Perindopril (prodrug), following hydrolysis to perindoprilat, inhibits angiotensin converting enzyme (ACE) both in vitro and in vivo.”
↗TGA PIT1✓

Plasma half-life is approximately one hour. The terminal half-life of the unbound fraction is approximately 17 hours.↗TGA PIT1✓

At a glance

Also known as

TGA-approved indications

PBS-subsidised indications

Adverse effects

Common (top 5)

Serious

Contraindications

Mechanism & pharmacology